2 recruiting, 1 not yet recruiting. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow pralsetinib: new trials by email Literature Review of pralsetinib trials Research Report on pralsetinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms | Phase 4 | Not yet recruiting | Fujian Medical University | 335 | 2025-07-01 | 2025-06-08 |
| A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy - Advanced Thyroid Cancer Patients Who Received Target Therapy | Phase 4 | Recruiting | Fudan University | 800 | 2020-01-01 | 2025-08-14 |
Thyroid Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1)
Fudan University (1) · Fujian Medical University (1) · Rigel Pharmaceuticals (1)
China (2) · Spain (1)
Dongmei Ji, M.D (1) · Qinghai Ji, M.D (1) · Yansong Lin, M.D (1) · Yu Wang, M.D (1)